Molecular engineering of a cryptic epitope in Spike RBD improves manufacturability and neutralizing breadth against SARS-CoV-2 variants
Name
1-s2.0-S0264410X22015973-main.pdf
Description
Published version
Size
1.84 MB
Format
Adobe PDF
Checksum (MD5)
f6fe0412234c8e1ce8e791ac2a81aac0
Author(s)
Rodriguez-Aponte, Sergio A
Dalvie, Neil C
Wong, Ting Y
Johnston, Ryan S
Naranjo, Christopher A
Bajoria, Sakshi
Kumru, Ozan S
Kaur, Kawaljit
Russ, Brynnan P
Lee, Katherine S
Date Issued
January 27, 2023
Journal
Vaccine
Publisher
Elsevier BV
Citation
Rodriguez-Aponte, Sergio A, Dalvie, Neil C, Wong, Ting Y, Johnston, Ryan S, Naranjo, Christopher A et al. 2023. "Molecular engineering of a cryptic epitope in Spike RBD improves manufacturability and neutralizing breadth against SARS-CoV-2 variants." Vaccine, 41 (5).
Version
Final published version
Abstract
There is a continued need for sarbecovirus vaccines that can be manufactured and distributed in low- and middle-income countries (LMICs). Subunit protein vaccines are manufactured at large scales at low costs, have less stringent temperature requirements for distribution in LMICs, and several candidates have shown protection against SARS-CoV-2. We previously reported an engineered variant of the SARS-CoV-2 Spike protein receptor binding domain antigen (RBD-L452K-F490W; RBD-J) with enhanced manufacturability and immunogenicity compared to the ancestral RBD. Here, we report a second-generation engineered RBD antigen (RBD-J6) with two additional mutations to a hydrophobic cryptic epitope in the RBD core, S383D and L518D, that further improved expression titers and biophysical stability. RBD-J6 retained binding affinity to human convalescent sera and to all tested neutralizing antibodies except antibodies that target the class IV epitope on the RBD core. K18-hACE2 transgenic mice immunized with three doses of a Beta variant of RBD-J6 displayed on a virus-like particle (VLP) generated neutralizing antibodies (nAb) to nine SARS-CoV-2 variants of concern at similar levels as two doses of Comirnaty. The vaccinated mice were also protected from challenge with Alpha or Beta SARS-CoV-2. This engineered antigen could be useful for modular RBD-based subunit vaccines to enhance manufacturability and global access, or for further development of variant-specific or broadly acting booster vaccines.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Koch Institute for Integrative Cancer Research at MIT
Massachusetts Institute of Technology. Department of Chemical Engineering
Ragon Institute of MGH, MIT and Harvard
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.vaccine.2022.12.062
